Literature DB >> 24189487

The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence.

Jeffrey M Witkin1, Michael A Statnick2, Linda M Rorick-Kehn2, John E Pintar3, Michael Ansonoff3, Yanyun Chen2, R Craig Tucker2, Roberto Ciccocioppo4.   

Abstract

Nociceptin/Orphanin FQ (N/OFQ) is a 17 amino acid peptide that was deorphanized in 1995. The generation of specific agonists, antagonists and receptor deficient mice and rats has enabled progress in elucidating the biological functions of N/OFQ. Additionally, radio-imaging technologies have been advanced for investigation of this system in animals and humans. Together with traditional neurobehavioral techniques, these tools have been utilized to identify the biological significance of the N/OFQ system and its interacting partners. The present review focuses on the role of N/OFQ in the regulation of feeding, body weight homeostasis, stress, the stress-related psychiatric disorders of depression and anxiety, and in drug and alcohol dependence. Critical evaluation of the current scientific preclinical literature suggests that small molecule modulators of nociceptin opioid peptide receptors (NOP) might be useful in the treatment of diseases related to these biological functions. In particular, the literature data suggest that antagonism of NOP receptors will produce anti-obesity and antidepressant activities in humans. However, there are also contradictory data discussed. The current literature on the role of N/OFQ in anxiety and addiction, on the other hand points primarily to a role of agonist modulation being potentially therapeutic. Some drug-like molecules that function either as agonists or antagonists of NOP receptors have been optimized for human clinical study to test some of these hypotheses. The discovery of PET ligands for NOP receptors, combined with the pharmacological tools and burgeoning preclinical data set discussed here bodes well for a rapid advancement of clinical understanding and potential therapeutic benefit.
© 2013.

Entities:  

Keywords:  (1S,3aS)-8- (2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl)-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one, a NOP receptor agonist; (±)trans-1-[1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one, a NOP receptor antagonist; 2-{3-[1-((1R)-acenaphthen-1-yl)piperidin-4-yl]-2,3-dihydro-2-oxo-benzimidazol-1-yl}-N-methylacetamide, a NOP receptor agonist; 5-HT; 5-hydroxytryptamine or serotonin; 8-[bis(2-methylphenyl)-methyl]-3-phenyl-8-azabicyclo[3.2.1]octan-3-ol; ACTH; Alcohol-preferring rats; Anxiety; BED; BNST; CGRP; CPP; CRF; CTA; Calcitonin gene related peptide; CeA; DA; Depression; Drug dependence; EPSC; FST; G-protein activated, inwardly rectifying K(+) channel; G-protein-coupled receptor; GIRK; GPCR; HPA; J-113397; JTC-801; KO; MDD; Marchigian Sardinian Alcohol-Preferring; N-(4-amino-2-methylquinolin-6-yl)-2-(4-ethylphenoxymethyl)benzamide hydrochloride, a NOP receptor antagonist; N/OFQ; NAcc; NE; NOP; NPY; Nociceptin opioid peptide or Nociceptin opioid peptide receptor; Nociceptin/Orphanin FQ; Nociceptin/Orphanin FQ (F: phenylalanine, Q: glutamine, the amino acids that begin and end the peptide sequence); ORL; Obesity; P rats; POMC; Pro-opiomelanocortin; Ro 64-6198; SB-612111; SCH 221510; SCH 655842; Stress; TST; UFP-101; VTA; W212393; [(–)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol, a NOP receptor antagonist; [Nphe(1),Arg(14),Lys(15)]N/OFQ-NH(2), a NOP receptor antagonist; adrenocorticotropic hormone; bed nucleus of stria terminalis; binge eating disorder; central nucleus of the amygdala; conditioned place preference; conditioned taste aversion; corticotrophin-releasing factor; dopamine; endo-8-[bis(2-chlorophenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]octane-3-carboxamide, a NOP receptor agonist; excitatory post-synaptic current; forced-swim test; hypothalamic–pituitary axis; knockout; mPFC; major depressive disorder; medial prefrontal cortex; msP; neuropeptide Y; norepinephrine; nucleus accumbens; opioid-receptor-like; tail-suspension test; ventral tegmental area

Mesh:

Substances:

Year:  2013        PMID: 24189487      PMCID: PMC5098338          DOI: 10.1016/j.pharmthera.2013.10.011

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  198 in total

1.  Functional expression, activation and desensitization of opioid receptor-like receptor ORL1 in neuroblastoma x glioma NG108-15 hybrid cells.

Authors:  L Ma; Z J Cheng; G H Fan; Y C Cai; L Z Jiang; G Pei
Journal:  FEBS Lett       Date:  1997-02-10       Impact factor: 4.124

2.  Partial loss of tolerance liability to morphine analgesia in mice lacking the nociceptin receptor gene.

Authors:  H Ueda; T Yamaguchi; S Tokuyama; M Inoue; M Nishi; H Takeshima
Journal:  Neurosci Lett       Date:  1997-11-21       Impact factor: 3.046

Review 3.  A systematic review of variables associated with the relationship between obesity and depression.

Authors:  K Preiss; L Brennan; D Clarke
Journal:  Obes Rev       Date:  2013-06-30       Impact factor: 9.213

4.  Further characterization of the prototypical nociceptin/orphanin FQ peptide receptor agonist Ro 64-6198 in rodent models of conflict anxiety and despair.

Authors:  Celia Goeldner; Will Spooren; Jürgen Wichmann; Eric P Prinssen
Journal:  Psychopharmacology (Berl)       Date:  2012-01-18       Impact factor: 4.530

5.  Buprenorphine's effects on self-administration of smoked cocaine base and orally delivered phencyclidine, ethanol and saccharin in rhesus monkeys.

Authors:  M E Carroll; G N Carmona; S A May; S Buzalsky; C Larson
Journal:  J Pharmacol Exp Ther       Date:  1992-04       Impact factor: 4.030

6.  Divergence of the feeding and thermogenic pathways influenced by NPY in the hypothalamic PVN of the rat.

Authors:  C M Kotz; J E Briggs; M K Grace; A S Levine; C J Billington
Journal:  Am J Physiol       Date:  1998-08

7.  Acquisition, expression, and reinstatement of ethanol-induced conditioned place preference in mice: effects of opioid receptor-like 1 receptor agonists and naloxone.

Authors:  A Kuzmin; J Sandin; L Terenius; S O Ogren
Journal:  J Pharmacol Exp Ther       Date:  2003-01       Impact factor: 4.030

8.  The anxiolytic-like effects of the novel, orally active nociceptin opioid receptor agonist 8-[bis(2-methylphenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]octan-3-ol (SCH 221510).

Authors:  Geoffrey B Varty; Sherry X Lu; Cynthia A Morgan; Mary E Cohen-Williams; Robert A Hodgson; April Smith-Torhan; Hongtao Zhang; Ahmad B Fawzi; Michael P Graziano; Ginny D Ho; Julius Matasi; Deen Tulshian; Vicki L Coffin; Galen J Carey
Journal:  J Pharmacol Exp Ther       Date:  2008-05-20       Impact factor: 4.030

Review 9.  Brain dopamine and reward.

Authors:  R A Wise; P P Rompre
Journal:  Annu Rev Psychol       Date:  1989       Impact factor: 24.137

10.  Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers.

Authors:  Mark K Greenwald; Chris-Ellyn Johanson; David E Moody; James H Woods; Michael R Kilbourn; Robert A Koeppe; Charles R Schuster; Jon-Kar Zubieta
Journal:  Neuropsychopharmacology       Date:  2003-11       Impact factor: 7.853

View more
  65 in total

Review 1.  Nociceptin Opioid Receptor (NOP) as a Therapeutic Target: Progress in Translation from Preclinical Research to Clinical Utility.

Authors:  Nurulain T Zaveri
Journal:  J Med Chem       Date:  2016-03-14       Impact factor: 7.446

2.  Nociceptin Receptors in Alcohol Use Disorders: A Positron Emission Tomography Study Using [11C]NOP-1A.

Authors:  Rajesh Narendran; Roberto Ciccocioppo; Brian Lopresti; Jennifer Paris; Michael L Himes; N Scott Mason
Journal:  Biol Psychiatry       Date:  2017-05-31       Impact factor: 13.382

3.  Nociceptin receptor activation does not alter acquisition, expression, extinction and reinstatement of conditioned cocaine preference in mice.

Authors:  G C Sartor; S K Powell; H J Wiedner; C Wahlestedt; S P Brothers
Journal:  Brain Res       Date:  2015-12-03       Impact factor: 3.252

4.  The affective dimension of pain as a risk factor for drug and alcohol addiction.

Authors:  Dana M LeBlanc; M Adrienne McGinn; Christy A Itoga; Scott Edwards
Journal:  Alcohol       Date:  2015-05-01       Impact factor: 2.405

5.  A Novel and Selective Nociceptin Receptor (NOP) Agonist (1-(1-((cis)-4-isopropylcyclohexyl)piperidin-4-yl)-1H-indol-2-yl)methanol (AT-312) Decreases Acquisition of Ethanol-Induced Conditioned Place Preference in Mice.

Authors:  Nurulain T Zaveri; Paul V Marquez; Michael E Meyer; Willma E Polgar; Abdul Hamid; Kabirullah Lutfy
Journal:  Alcohol Clin Exp Res       Date:  2018-01-19       Impact factor: 3.455

Review 6.  Targeting opioid dysregulation in depression for the development of novel therapeutics.

Authors:  Caroline A Browne; Irwin Lucki
Journal:  Pharmacol Ther       Date:  2019-04-30       Impact factor: 12.310

7.  NOP agonists prevent the antidepressant-like effects of nortriptyline and fluoxetine but not R-ketamine.

Authors:  Victor A D Holanda; Wilton B Santos; Laila Asth; Remo Guerrini; Girolamo Calo'; Chiara Ruzza; Elaine C Gavioli
Journal:  Psychopharmacology (Berl)       Date:  2018-08-25       Impact factor: 4.530

8.  Analysis of key genes and micro-RNA-mRNA regulatory networks in women with ulcerative interstitial cystitis/pain bladder syndrome.

Authors:  Shengzhuo Liu; Shijian Feng; Deyi Luo
Journal:  Int Urogynecol J       Date:  2018-11-19       Impact factor: 2.894

9.  Genetic Deletion of the Nociceptin/Orphanin FQ Receptor in the Rat Confers Resilience to the Development of Drug Addiction.

Authors:  Marsida Kallupi; Giulia Scuppa; Giordano de Guglielmo; Girolamo Calò; Friedbert Weiss; Michael A Statnick; Linda M Rorick-Kehn; Roberto Ciccocioppo
Journal:  Neuropsychopharmacology       Date:  2016-08-26       Impact factor: 7.853

Review 10.  Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.

Authors:  Lawrence Toll; Michael R Bruchas; Girolamo Calo'; Brian M Cox; Nurulain T Zaveri
Journal:  Pharmacol Rev       Date:  2016-03-08       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.